# A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Source: https://onco.cc/trials/nct07196644/  
OnCo record `nct07196644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telisotuzumab adizutecan in advanced solid tumours, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan is a phase 2 interventional study registered as NCT07196644 by AbbVie, with 100 participants planned, started 2025-12-01 and due to reach its primary completion in 2030-12. Interventions recorded: Telisotuzumab Adizutecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07196644
- Phase: 2
- Setting: A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
- Sponsor: AbbVie
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07196644: https://clinicaltrials.gov/study/NCT07196644

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07196644.json